VistaGen Therapeutics

$0.751
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0269 (-3.38%) Today
-$0.019 (-2.47%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell VTGN and other stocks, options, and ETFs commission-free!

About VTGN

VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. The listed name for VTGN is VistaGen Therapeutics, Inc. Common Stock.

CEO
Shawn K. Singh
Employees
9
Headquarters
South San Francisco, California
Founded
1998
Market Cap
43.24M
Price-Earnings Ratio
Dividend Yield
Average Volume
744.49K
High Today
$0.795
Low Today
$0.726
Open Price
$0.78
Volume
653.29K
52 Week High
$1.06
52 Week Low
$0.30

Collections

VTGN Earnings

-$0.15
-$0.10
-$0.05
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
per share
Actual
Expected Feb 11, After Hours

You May Also Like